Please login to the form below

Not currently logged in
Email:
Password:

Lilly's Alzheimer's drug solanezumab stumbles, but doesn't fall in phase III

Fails to show significant benefit, but data holds some consolation

Eli Lilly & Company headquarters

Two phase III trials of Eli Lilly's amyloid-targeting antibody solanezumab failed to show a significant benefit in patients with Alzheimer's disease, following in the footsteps of rival drug bapineuzumab from Pfizer.

There was some comfort to be drawn from the data, however, as Lilly reported that a "statistically significant slowing of cognitive decline" was seen when the studies were pooled, with the benefit accounted for by a subgroup of patients with mild symptoms of the disease.

Like Pfizer's bapineuzumab, solanezumab did not meet cognitive and functional endpoints in the 18-month EXPEDITION 1 and 2 phase III trials but - in light of the cognitive decline data - Lilly said it now intends to discuss the results with regulatory authorities.

The finding lends some credence to the notion that solanezumab and bapineuzumab were given too late in the disease development process, and earlier intervention with amyloid-targeting therapies could still be of benefit.

It also provides some much-needed support for the amyloid hypothesis of Alzheimer's, which holds that the amyloid plaques seen in the brains of patients with the disease are a key factor in the neurodegenerative process and breaking them down - or more likely blocking their formation - can interrupt disease progression.

"We believe the pooled data support the amyloid hypothesis, as these are the first phase III data with an anti-beta amyloid agent that appear to show a slowing of cognitive decline," commented Jan Lundberg, president of Lilly Research Laboratories.

While the future of the programme is decided Lilly is pressing ahead with an open-label extension of the studies, called EXPEDITION-EXT, which will allow the company to collate data on longer-term use of the drug.

If Lilly gets a favourable response from regulators and opts to continue development of solanezumab it represents a surprise upside for the company, given that pharma observers had given the drug only a slim chance of success.

The lack of disease-modifying therapies for Alzheimer's means any medicine that secured approval in this setting would likely become a blockbuster, although analysts still believe the chances of solanezumab reaching the market are low.

Approval may also require additional clinical studies, and observers note that Lilly may baulk at paying the hefty price tag for another large-scale study of the drug, while not ruling out the possibility of filing even with the current dataset.

28th August 2012

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hall & Partners

We are a specialist brand and communications research consultancy offering you fresh ideas at every stage of the brand planning...

Latest intelligence

quantify_messages.png
Meet expert speakers: The right e-detailing content for rich data
We are excited to reveal the names of the expert speakers at Anthill's next webinar "The right e-detailing content for rich data" on the 3rd June 2015, 3 PM GMT+2....
Can rare diseases be a viable option for the pharma industry?
In this article, Christopher Ehinger questions whether rare diseases are a viable option for the pharma industry. He looks at the total number of approvals and orphan drug designations in...
How do you solve a problem like non-adherence? Part 2
Following her previous piece on patient medical non-adherence, Head of Customer Experience Elisa del Galdo takes a look at the different patient personas that emerge during the diagnosis and treatment...

Infographics